-
Tyligand Bioscience Appoint Dr. Xiao Kai as Vice President
2021-09-01
On August 2, 2021, Tyligand Bioscience (Shanghai) Co., Ltd. announced the appointment of Dr. Xiao Kai as Vice President, responsible for Corporate and Business Development.
查看详情
-
Tyligand Bioscience appoints Dr. Cong Lei as Sr. VP of Clinical Development
2021-08-01
Tyligand Bioscience (Shanghai) Limited, a leading innovation-driven, clinical stage biotech, announced the appointment of Cong Lei, MD/PhD, as Senior Vice President of Clinical Development, where she will be responsible for formulating inn ...
查看详情
-
Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
2020-03-13
Tyligand Bioscience and Phildelphia based biotech Context Therapeutics announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER).
查看详情
-
Tyligand Bioscience Aquired ONA-XR (Onapristone sustained relese) right of development and commercialization in Greater China
2021-08-25
Context and Tyligand entered into a license agreement whereby Tyligand was granted the exclusive right and sole responsibility for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the “Territory”), and Contex ...
查看详情